The company was founded in 2012 and has since created the Nebula Antibody platform, which has been supported by numerous entrepreneurship and scientific awards. They have collaborated with various North American and European pharmaceutical partners and have produced over 350 commercial antibodies while submitting several patents for their technologies. In 2015, they initiated their own antibody pipeline, with a primary focus on cancer and gastrointestinal health, and have advanced 4 candidates to late stages of discovery. Their unique discovery platform addresses the challenges related to GPCR and membrane protein antibody discovery by using the untapped chicken antibody repertoire to target conserved mammalian proteins, proprietary Spatial Peptides reproducing the target’s 3D conformation, phage display technologies combined with NGS to select the best recombinant antibody candidates, and efficient humanization formatting. They also have a biomanufacturing capacity to produce antibodies and other protein compounds, which has allowed them to successfully enter an internal program into clinical trials.